✦ LIBER ✦

5052 An open-label, single arm study of lapatinib and capecitabine in Chinese women with advanced or metastatic breast cancer (MBC)

✍ Scribed by B. Xu; Z. Jiang; D. Chua; Z. Shao; R. Luo; X. Wang; B. Newstat; H. Chi; G. Chen; L. Wang

Book ID: 119600702
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 46 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70944-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcomes of HER2-positive metas

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

✍ Jungsil Ro, Sohee Park, Sung- Bae Kim, Tae You Kim, Young Hyuk Im, Sun Young Rha 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 287 KB

A single-arm, multicenter, open-label ph

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

✍ Christian Wülfing; Jean-Pascal H. Machiels; Dirk J. Richel; Marc-Oliver Grimm; U 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

2123 POSTER MO19391: an open-label safet

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

✍ I.E. Smith; L. Biganzoli; H. Cortes-Funes; F. Franke; Y. Mostafa Kamel; J.Y. Pie 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A multicenter, nonrandomized, open-label

A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer

✍ G. Konecny; N. Finkler; P. Lee; A. Yovine; A. Liu; P. Sen; M. Squires; A. Kay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB

Erratum to: A phase II open-label random

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 61 KB